A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
Idiopathic Inflammatory Myositis (IIM)
Systemic Sclerosis (SSc)
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis

Interventions

DRUG: FT819
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Bendamustine

Sponsor

Fate Therapeutics